EZH2 and posterior cortical atrophy: Furthermore, the use of anti-EZH2 and anti-HCMV therapies could open the door to new avenues that might be beneficial in the management of PCa, especially the more aggressive castration-resistant ones, such as hormone-refractory PCa with high metastatic potential.